Tumor-associated antigens presented via Hsp96 complexes — Drug Target

All drugs that target Tumor-associated antigens presented via Hsp96 complexes — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

Autologous therapeutic cancer vaccine

Phase 3 pipeline (1)

• HSPPC-96 or Oncophage · Agenus Inc. · Autologous therapeutic cancer vaccine · Oncology
  HSPPC-96 is a personalized cancer vaccine that uses heat shock protein-peptide complexes derived from a patient's own tumor to stimulate immune recognition and destruction of cancer cells.